Breast Cancer Screening: Implications and Clinical Perspectives  by Guraya, Salman Yousuf
67 
 
 
 
Breast Cancer Screening: 
 Implications and Clinical Perspectives 
 
Salman Yousuf Guraya FRCS  
 
Department of Surgery, College of Medicine 
 Taibah University, Al Madina Al Munawara 
Kingdom of Saudi Arabia 
 
 
 
 
 
REVIEW ARTICLE 
 
Abstract 
Background 
In the developed countries, breast cancer is the most commonly diagnosed malignancy in 
women and the global incidence of breast cancer is still increasing worldwide. Breast 
cancers can be detected during breast cancer screening program which offers the best 
chance to treat the disease at an earlier stage. Currently, there is no established breast 
cancer screening program in the Kingdom of Saudi Arabia.  
Objective  
To address the objective significance of breast cancer screening, which detects and localizes 
breast cancer through a well-structured system of public awareness and follow up program? 
Treatment of breast cancer at an early stage will provide the maximum chance of cancer-cure 
with resultant better prognosis. 
Methods 
A systematic literature search of English-language articles on MEDLINE, the Cochrane 
database of evidence-based reviews, and the Database of Abstracts of Reviews of Effects 
was performed for the period 1988-2008. Keywords "breast cancer", "breast cancer 
screening program", "mammography", and "PET scan" were used for literature review. The 
breast cancer screening programs in various regions of the world were explored regarding 
the components of the screening program, strengths and weaknesses of each component, 
and the inference derived from the literature.  
Conclusion  
Breast cancer screening program has a well-established role in the detection of early, 
impalpable, and asymptomatic lesions with consequent reduction of cancer-associated 
morbidity and mortality.  
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Introduction 
 
here is a persistently escalating 
incidence of breast cancer worldwide 
and the same is reflected in the Kingdom of 
Saudi Arabia. Breast cancer, if left untreated 
or per se undiagnosed, will disseminate and 
manifest as systemic ailment. The 
underlying premise for breast cancer 
screening is that it allows the detection of 
breast cancers before they become palpable. 
Breast cancer is a progressive disease, and 
small tumors are more likely to be at early 
stage disease, have a better prognosis, and 
are more successfully treated. Screening 
refers to the testing of asymptomatic 
individuals for the detection of occult 
disease. Early detection employs the 
application of a technique or strategy that 
results in earlier diagnosis of non-palpable, 
as well as palpable, breast cancers. Last 
decade has witnessed a thumping success 
after the introduction of various breast 
cancer screening programs across the globe. 
Such programs reported substantial 
reduction in the cancer related morbidity 
and mortality due to the detection of breast 
cancer at an early stage1. 
The benefits of breast cancer screening 
program spring from the fact that the earlier 
detection of breast cancer allows complete 
control of the disease process with resultant 
improved prognosis and reduced morbidity 
and mortality. At the same time, regional 
Cancer Registry Offices get authentic data of 
breast cancer incidence, clinical features, 
stage and age at presentation, risk factors, 
and the efficacy of screening and diagnostic 
techniques.  
Currently, there is no established national 
breast cancer screening program in the 
Kingdom of Saudi Arabia; although a 
number of breast cancer awareness 
campaigns have been launched which 
educate the masses about the importance of 
breast cancer screening.   The core objective 
of the present study is to emphasize the 
significance of breast cancer screening 
programs worldwide necessitating the need 
for the execution of such screening program 
in the Kingdom of Saudi Arabia. This would 
also provide the opportunity to assess the 
efficacy of various screening tools being 
employed for the breast cancer screening 
including mammography, clinical 
examination by the specialist, and breast 
self-examination. 
  
Literature Review 
 
In the developed countries, breast cancer is 
the most commonly diagnosed malignancy 
in women and the global incidence is still 
increasing2. Although breast cancer is the 
commonest cancer among women 
worldwide3, this cancer has emerged as the 
most frequent female malignancy in the 
majority of Asian countries, but remains the 
second commonest female malignancy in 
some regions of the developing Asian 
countries, next to the cancer of uterine 
cervix4. 
In 2007, the population of the Kingdom of 
Saudi Arabia (KSA) was estimated to be 27 
million, with half of the Saudi population 
under the age of 20 years5. The National 
Cancer Registry (NCR) of the KSA, a 
population-based registry, reported 783 
(24.3%) cases of breast cancers among 
females population6. Breast cancer ranks less 
highly (fifth) as a cause of death because of 
the relatively favorable prognosis where 
mortality-to-incidence ratio is 0.357. The 
overall pattern of breast cancer mortality 
reveals high rates for Western, 
industrialized nations and lower rates for 
less industrialized and Asian nations8. 
Age-standardized ratio (ASR) is a summary 
measure of the cancer rate that a population 
would have if it had a standard age 
structure9. It appears that ASR in the KSA 
did not show any significant rising trend 
over a 10-year calendar period 1994-2003 
(16.2-18.2 per 100,000 women). This steady 
pattern is similar to that in the United States 
of America (USA) prior to the 
implementation of breast screening program 
(1974-1983)7. On the other hand, the ASR in 
the USA during the 1980s and 1990s showed 
a steady increase. This materialized due to 
meticulous screening protocols and more 
detection of breast cancer cases. 
Recently, breast cancer mortality rates in 
selected countries have been falling10, 11. This
T 
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 is mainly attributed to the execution of 
well-structured breast cancer screening 
programs worldwide. Since 1980s, many 
countries have introduced breast cancer 
screening programs to detect malignancies 
at an earlier, non palpable stage, which 
would help to reduce the breast-cancer 
associated morbidity and mortality12, 13. Not 
only the prevalence of breast screening but 
also the increased detection of early stage 
cancer in all age groups have resulted from 
improvements in diagnostic technology and 
heightened social interest14. The World 
Health Organization’s International Agency 
for Research on Cancer (IARC) calculated a 
35% drop in the mortality rate from breast 
cancer in the UK15. In other words, one life 
was saved in each group of 500 women who 
participated in the breast screening. It is also 
anticipated that the incidence of early breast 
cancer would drop from 49% to 43%16, and 
the mortality rate of the subject age group 
will be reduced by half in 201017. Despite a 
worldwide acceptance and established 
effectiveness of breast cancer screening 
programs, some published reports indicated 
that screening was unjustified because there 
was no reliable evidence that it reduced 
mortality18. Evidence based studies have 
elucidated the effectiveness of breast cancer 
screening and testified its role in reduction 
of morbidity and mortality of breast cancer. 
Screening refers to tests and examinations 
employed to find a disease, such as cancer, 
in people who do not have any symptoms. 
The goal of screening techniques is to find 
cancers before they start to cause symptoms. 
This employs the application of a technique 
or strategy that results in earlier diagnosis of 
non-palpable, as well as palpable, breast 
cancers than otherwise would have 
occurred. Breast cancers that are found 
because they can be felt tend to be larger 
and are more likely to have already spread 
beyond the breast. In contrast, breast cancers 
found during screening examinations are 
more likely to be small and still confined to 
the breast. Although screen-detected breast 
cancers are associated with reduced 
morbidity and mortality, the majority of 
women who participate in screening will 
not develop breast cancer in their lifetime. 
Screening also will not benefit all women 
who are diagnosed with breast cancer, and it 
leads to harms in women who undergo 
biopsy for abnormalities that are not breast 
cancers, as well as those who are 
overtreated for ductal carcinoma in situ 
(DCIS) that might have been 
nonprogressive. Thus, in addition to 
benefits, limitations and harms associated 
with screening needs to be addressed. Other 
untoward effects of breast cancer screening 
include patients' apprehension, financial 
burdens, false positive cases, and false 
reassurance to false negative. 
 
Organization of Breast Cancer 
Screening Program 
 
The National Health Service Breast 
Screening Program (NHSBSP) in the UK has 
set out a clear protocol in the Forrest Report 
of 198617. This report considered a single 
medio-lateral oblique view of mammogram, 
clinical examination, breast self-
examination, and combinations of these 
techniques as potential screening modalities. 
Originally, women aged 50-64 years were 
invited for screening every three years, with 
the extension of age-limit to 70 years being 
applied from 2004 onwards. Women older 
than the invited age range are entitled to 
screening every three years on request 
(Figure 1). 
Depending on the defined age group to be 
included in the breast cancers screening 
program, mammography is performed for 
the invited women. 
1. Based on the recommendations by BI-
RADS by ACR (Breast Imaging 
Reporting And Data System by the 
American College of Radiologists), 
mammographic findings are categorized 
as: 
a. Category 0, Needs additional imaging 
evaluation (additional mammographic 
views or breast ultrasound to evaluate 
the lesion). 
b. Category 1, Negative (no abnormality 
noted). 
c.  Category 2, Benign findings (benign 
calcifications, fat containing masses, 
intrammamary lymph nodes, but  
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Figure 1: Organization of a breast cancer screening program19.  
 
 
nothing to suggest malignancy). 
d. Category 3, Probably benign findings; 
short interval follow-up by a 6-month 
unilateral mammogram with additional 
views that best demonstrates the lesion, 
and 12-, 24-, and 36-month bilateral 
mammograms. 
e. Category 4, Suspicious abnormality; 
density, microcalcifications, spiculated 
mass.  
f.  Category 5, Highly suggestive of 
malignancy; architectural distortion, 
asymmetry of breast parenchyma, along 
with category 4 findings  
2. Women with BI-RADS categories 4 and 
5 are recalled to the hospital-based 
Specialist Assessment Clinic for triple 
assessment (clinical examination, 
further imaging by spot magnification 
views and ultrasound, and FNAC, core 
biopsy, or open surgical biopsy).  
3. The Specialist Assessment Clinic is run 
by the involved surgeons and 
radiologists, and the pathologist is 
available during the session if  
 
 
 
immediate reporting of the biopsy is 
required.   
4. For the impalpable breast lesions, 
ultrasound-guided FNAC using 21-
guage needles is performed in the 
radiology department. 
5. The pathology results of the FNAC or 
core biopsy specimens are divided into: 
a. Insufficient aspirate or tissue; needs 
repeat test 
b. Benign breast disease 
c. High risk lesions; atypical cytology, 
atypical ductal hyperplasia, atypical 
lobular hyperplasia, lobular carcinoma 
in situ 
d. Malignant breast disease; ductal 
carcinoma in situ, and invasive breast 
cancer 
6. The patient diagnosed to have breast 
cancer is further discussed at the 
scheduled meetings by specialist 
surgeons for further management. 
Currently, 75% of invited women attend for 
screening20 while the national minimum 
standard for attendance is 70%21 (Figure 2).  
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 Figure 2: Minimum standards as defined by the National Health Service Breast Cancer Screening 
Program20.  
 
Basic screening mammography takes place 
either at a static or mobile breast screening 
unit. Film processing is done at the static 
unit, where films are also read and reported. 
About 5% of women screened are recalled 
for further investigations because their basic 
screening mammogram shows some 
abnormalities22. Majority of breast cancers 
are diagnosed pre-operatively on the basis 
of triple assessment; breast clinical 
examination (BCE), fine needle aspiration 
and cytology (FNAC), and mammography. 
About 0.3% of all women screened require 
an open biopsy to establish a definite 
diagnosis, and 0.6% of all women screened  
 
are diagnosed with breast cancer and 
referred for treatment to a specialist breast 
cancer surgeon17. Since microcalcifications 
can be detected only by mammography, the 
incidence of Ductal Carcinoma in Situ 
(DCIS) increased about two-fold after the 
introduction of screening in the UK23. 
However, the proportion of DCIS has been 
less than 10% of the total number of breast 
cancer cases and will make a limited 
contribution to the mortality improvement. 
On the other hand, the actual increase in the 
mortality rate from breast cancer slowed 
down by 12% from the estimated rates in 
1996-200024 (Figures 3 and 4). 
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Figure 3: Cancers detected by NHSBSP in England for invited women aged over 45 years24. 
 
  
 
 Figure 4: Age specific breast cancer registration rates, England and Wales, 1971–2001. 
The age groups most affected by the NHSBSP are shown in bold P24 
 
In 1995, NHSBSP conducted a randomized 
controlled trial of single- versus double-
view screening mammogram, second view 
being the cranio-caudal, and showed that 
the second view increased the detection of 
breast cancers by 24% and reduced the recall 
rate by 15%P25P. This prompted the 
management of  breast  cancer   screening 
program to add second view mammogram 
 all over the UK since 2004. 
According to the American College of 
Surgeons updated Breast Cancer Screening 
Guidelines, women are advised to get a 
mammogram every year, starting at age 40, 
and as long as a woman is in good health, 
she should continue getting routine 
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mammograms26. Women with a higher than 
average risk for breast cancer; (those who 
have already had the disease, or who have a 
positive family history, or with a genetic 
mutation that greatly increases their risk of 
developing it) are encouraged to discuss the 
possibility of beginning screening earlier (at 
age 30, or in rare cases even younger). The 
updated guidelines also have clarified the 
role of the BCE (a physical examination of 
the breasts by a health care professional). 
The updated guidelines recommend women 
get a BCE as part of their regular physical 
check up (about every three years for 
women 20-39, and yearly for women 40 and 
older), and encourage them to use the 
opportunity to talk with their healthcare 
provider about breast health: what’s normal 
and what isn’t, breast cancer risk factors, 
early detection testing, and the importance 
of bringing any changes to a doctor’s 
attention quickly.  
Recommendations for breast self-
examination (BSE) have been updated as 
well. Beginning in their 20’s, women should 
be told about the benefits and limitations of 
BSE, and that it is acceptable for women to 
choose not to do BSE, or to do it 
occasionally. The importance of promptly 
reporting changes to a physician is 
emphasized. The reason for this change is 
that BSE plays a very limited role in 
detecting breast cancer compared with self 
awareness. Often, women who do detect 
their own breast cancer find it outside of a 
structured breast self-exam; they may detect 
a lump while showering or getting dressed. 
The updated guidelines recognized that 
mammography is still the gold standard for 
screening, and new technologies must equal 
or exceed its performance in order to be 
recommended as screening tools.  
In the Netherlands, a nation-wide breast 
cancer screening program was gradually 
implemented from 1989 till 199727, where all 
women aged 50-75 were invited to attend 
biennial screening mammogram. Duijn et 
al28 conducted a pilot study to interpret the 
10-year screening results, and concluded 
that the screening protocol with biennial 
mammogram detected 90% of the breast 
cancers pre-operatively. 
On the contrary, there have been no 
concrete studies available which could 
objectively compare data and facts relating 
to breast cancer in the developed, newly 
developed, and developing countries thus 
far in Asia. A lack of credible and 
scientifically sound epidemiological data on 
breast cancer from the developing Asian 
countries makes it difficult to understand 
the reasons for the different breast cancer 
incidence, mortality, and outcomes in these 
countries. Agarwal et al29   conducted a 
multi-national, retrospective, and 
collaborative study by comparing the 
demographic, clinical, pathological, and 
outcomes data in breast cancer patients 
managed at participating breast cancer 
centers in India, Malaysia, and Hong Kong. 
They reported the age-adjusted cancer rates 
of 24.8-33.4 per 100,000 of the population, 
which amounted to be about one-third of 
the incidence reported from western 
countries such as the USA (109.6 per 
100,000)30. There seems to be numerous 
plausible reasons for differences in breast 
cancer incidence. The low average life 
expectancy of women in the developing 
Asian countries has a bearing on the 
incidence of breast cancer, which has a 
known correlation with increasing age; late 
menarche related to under-nutrition, early 
menopause, bearing many children, and 
breast feeding are the other logical 
explanations. Asian diets in general have 
less fat and higher fiber content, which has 
been suggested, albeit with questionable 
validity, to have some protective effect 
against breast cancer30, 31. Inadequacies of 
health care facilities and infrastructure, 
socioeconomic barriers, illiteracy, and non-
existent breast cancer screening programs 
play pivotal role in underestimated 
incidence of cancer cases. This further 
substantiates the need for a well-structured 
breast cancer screening in the KSA which 
would unfold the real data for further 
analysis. 
Traditional breast cancer risk factors include 
a family history of breast cancer, nulliparity, 
late age at first child, early menarche, late 
menopause, personal history of atypia or 
lobular carcinoma in situ, and history of
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contralateral breast cancer33. Breast cancer is 
also encountered more frequently in women 
with genetic hereditary syndromes such as 
Cowden’s Syndrome and BRCA 1 and 
BRCA 2 mutation families. Current options 
to screen this high risk group are close 
surveillance, annual or biannual clinical 
breast examination at 25-35 years of age, 
annual mammography starting between the 
ages of 25 and 35 years, and BSE by the age 
18-21 years of old34.  Many aggressive 
surveillance programs have been developed 
using advanced MRI, Positron Emission 
Tomogram (PET) scan, PET/CT scan, and 
reductions in breast cancer risk of 50% or 
more have been proven using 
chemoprevention strategies with tamoxifen 
and raloxifene35. Similarly, Hartman36 of The 
Mayo Clinic applied preventive surgery for 
high-risk patients and found a 90% 
reduction among 639 cases in women with 
moderate and high risk determinants for 
breast cancer. McDonnell et al37 documented 
the clinical efficacy of contralateral 
prophylactic mastectomy in women with a 
personal and family history of breast cancer, 
while Van Geel38 reported a 100% risk 
reduction after prophylactic mastectomy. 
Genetic testing for BRCA 1 and BRCA 2 
mutations documented that BRCA 1 and 
BRCA 2 accounted for about 20-40%, and 
30% of all hereditary causes of breast 
cancer39. Such advanced breast cancer 
screening methods, using latest imaging and 
genetic gadgets, have shown tremendous 
promise and can be the future tools to detect 
early breast cancer during the course of 
cancer screening of the general population.  
 
Imaging Modalities for Detection of 
Breast Cancer 
 
As previously mentioned, all the existing 
breast cancer screening programs 
worldwide rely heavily on mammography 
that has led to a significant reduction in 
breast cancer mortality40, 41. The depiction of 
fine microcalcifications and subtle soft-
tissue masses is a key to the detection of 
early breast cancer (Figure 5). The 
advantages  of  mammography  are the high  
 
  
 Figure 5: Mammogram showing
microcalcification of ductal carcinoma in situ 
  
spatial resolution, the convenient display, 
and inexpensiveness. However, 
mammography also has limitations: it will 
miss some cancers, and it sometimes leads 
to follow-up of findings that are not cancer, 
including biopsies. At the same time, 
narrow dynamic range, low contrast 
resolution, the difficulty of postprocessing, 
and film artefacts that contribute to a known 
false-negative rate of up to 10% in the 
detection of breast cancer, are other soaring 
problems encountered with conventional 
mammography P42P. Mammographic accuracy; 
88% breast cancers correctly diagnosed by 
radiologist, 27% breast cancers detected only 
by mammography, 8% misinterpreted, and 
4% breast cancers are not detected by 
mammography at all P43P. The filmless 
environment created by the Picture 
Archiving and Communication Systems 
(PACS) enables more efficient storage, 
retrieval, and transmission of images. PACS 
has also improved radiology services by 
allowing complete control of runaway film 
problem i.e., reducing the number of lost 
films and also reducing the rates of 
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unreported films44. Until quite recently, 
conventional mammography is still not 
available on the PACS, while a new version, 
digital mammography can be directly 
interfaced with the PACS. Looking into 
certain limitations of conventional 
mammography, a number of high-definition 
imaging techniques has been commercially 
introduced.   
Positron Emission Mammography (PEM), a 
new technique for imaging the breast, is not 
affected by either breast density or a 
woman's hormonal status, two factors that 
limit the effectiveness of standard 
mammography and MRI at detecting 
cancer45. PEM is an application of high-
resolution Positron Emission Tomography 
(PET) for breast, where a radioactive 
material, 18F-flouro-2-deoxy-D-Glucose, is 
injected into the body to measure metabolic 
activity and determine the presence of 
disease (Figure 6).  
 
 
 
 
Figure 6: Positron Emission Tomogram (PET) 
showing increased tumor activity (arrow).  
 
 
Glucose is used by cells for energy and,  
since cancer cells use more energy, they take 
up more of the tracer and are highlighted on 
the image. The ability of standard 
mammography to detect lesions is reduced 
when performed on dense breasts, where 
tissue is less fatty and more glandular. 
Breast MRI is effective at detecting cancer in 
dense breasts and is increasingly being used 
to screen women at high risk for breast 
cancer. However, MRI has a high incidence 
of false-positive test results that indicate 
cancer is present when it is not. Researchers 
believe these false positives are due in part 
to hormonal changes that occur during a 
woman's menstrual cycle. Unless the MRI is 
performed on day 7 through 14 of a 
woman's cycle, reading MRI images are 
extremely difficult to interpret. Because 
hormones do not have the same effect on 
PEM results, this imaging technique could 
play a significant role both in preoperatively 
evaluation of breast cancer patients and in 
screening high-risk patients.  PEM is also 
ideal for patients with implants, metal in 
their bodies, or patients who suffer from 
claustrophobia.  
Breast-Specific Gamma Imaging (BSGI) is an 
emerging molecular imaging technology 
using a high-resolution gamma camera that 
allows for imaging with very mild 
compression of the breast along with an 
injection of a low-dose nuclear radiotracer, 
which is readily absorbed by the cells. 
Because cancerous cells have a higher rate of 
metabolic activity, the tracer is taken up by 
these cells at a higher level than in normal 
cells46. While mammography findings are 
characterized by the difference in 
appearance between normal and suspicious 
breast tissue, BSGI findings are based on 
how cancerous cells function. BSGI is 
effective in the detection of hard-to-detect 
breast cancers not found by clinical exam or 
where mammograms show only suspicious 
lesions. 
CT alone cannot accurately judge the tumor 
activity but has the advantage of precise 
anatomical localization of the tumor (Figure 
7). 
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Figure 7: CT Chest showing a tumor mass in the 
breast (arrow). 
A novel combination of Positron Emission 
Tomography by using 18F-flouro-2-deoxy-D-
Glucose (FDG-PET) and CT (PET/CT) of the 
breast has been applied to correctly localize 
and interpret FDG uptake. Many reports 
have confirmed the usefulness of FDG-PET 
to distinguish between malignant and 
benign tumors, to localize the tumor and 
detect lymph node involvement, to restage 
metastatic or recurrent disease, and to 
evaluate treatment response47-50. However, 
FDG-PET has lower sensitivity than 
magnetic resonance imaging (MRI) because 
of low spatial resolution51. It is difficult to 
detect the anatomical location of a tumor 
with FDG-PET alone. To overcome this 
problem, a contrast enhanced CT has been 
combined with FDG-PET with the patient in 
the same position. The two images are then 
fused and displayed on a computer 
workstation. These software-based fused 
images allow the accurate detection of the 
anatomical location of the tumor. However, 
with this method, it is difficult to 
synchronize PET and CT images, because 
these images are obtained at different times, 
and respiratory motion was shown to cause 
an incompletely fused image52. A combined 
PET/CT system addresses these problems, 
in that it allows functional PET and 
anatomical CT images to be acquired in one 
session and to be rapidly fused. Hayashi et 
al 53 detailed the steps of this latest imaging 
technique: Prior to the PET examination, 
patients fasted for at least 5 hours, and 60 
minutes after FDG injection, a 3-min static 
emission study was performed at the 
transmission position (early phase), and 
another scan for the delayed phase was 
performed 120 minutes after the injection. 
The attenuation-corrected images were 
reconstructed and used for anatomic 
localization of the PET. After a routine PET 
study, they performed a CT study with 
iodine contrast medium immediately with 
the patient in the same position. PET/CT 
has now established role to detect and 
localize primary breast lesion and 
differentiation between benign and 
malignant lesions54, to identify non-
responders to chemotherapy55, and in the 
diagnosis of local relapse and distant 
metastases53 (Figures 8 and 9).    
 
 
Figure 8: PET/CT. Accurate identification of the 
anatomical location of a tumor in the breast is 
difficult by PET alone because of its low spatial 
resolution. Fused image obtained by PET and 
CT53.  
 
The precise diagnosis by PET/CT demands 
a radiologist specialized in PET diagnosis 
who is highly experienced not only in 
examining general radiological images but 
also the nuclear medicine images. Moreover, 
on the clinical side, it is necessary to order 
such imaging studies after understanding 
the advantages and limitations of PET/CT 
imaging. 
MRI of the breast has emerged as a most 
sensitive modality for breast tumors. Breast 
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MRI has been found to be 94–99% sensitive 
for the detection of breast cancer56-58. In 
contrast, helical CT of the breast was used in 
Japan to evaluate breast cancer extent before 
surgery. In the recent years, multidetector 
CT (MDCT) has become commercially 
available for the detection of breast cancer. 
The greater spatial and temporal resolution 
of MDCT images compared with those 
obtained using single-detector helical CT 
suggests that the extent of breast cancer 
might be evaluated more accurately with 
MDCT (Figure 10).  
 
 
 
Figure 9: Breast cancer response to neoadjuvant 
chemotherapy before (a) and after (b) 
arrowheads53. 
 
 
Figure 10: Multidetector CT (MDCT) scan 
showing enhanced mass effect in left breast.  
 
Researchers59 compared the efficacy of 
MDCT and MRI and reported that MRI, 
albeit a high false positive rate, was more 
accurate for the detection of intraductal 
carcinoma and evaluation of breast cancer 
extent. MDCT, of course, is associated with 
the established risk of exposure to radiation.  
As a result of massive expansion in the field 
of breast imaging, there seems to be a 
wealth of diagnostic options to choose from. 
In reality, mammography remains the 
mainstay of breast cancer screening, and 
none of the aforementioned radiological 
modalities can replace mammography as 
the cornerstone of cancer detection. PEM, 
BSGI, PET/CT, MRI and MDCT are adjuncts 
to mammography which testifies its global 
application and substantial usefulness61-68. 
The primary evidence supporting the 
recommendation for periodic screening for 
breast cancer with mammography derives 
from seven randomized controlled trials. 
Two of the trials took place in North 
America, one in Scotland, and four in 
Sweden. One additional trial is underway in 
the United Kingdom evaluating the benefit 
of beginning screening in a woman’s early 
40s60. Individual trials and meta-analyses of 
all trials combined showed statistically 
significant mortality reductions of 40-47% 
for women aged 40 to 69 associated with an 
invitation to screening69-71. Breast cancer 
mortality reductions associated with
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 screening have been reported from the 
Florence, Italy Screening program, also 
comparing breast cancer mortality among 
attendees and non-attendees to screening, 
and in the population before and after the 
introduction of screening between 1990 and 
199672. The incidence-based mortality ratio 
(i.e., the rate of fatal incident breast cancer 
cases) comparing 1990 to 1996 with 1985 to 
1986 shows a 50% reduction in the rate of 
breast cancer deaths (RR = 0.50, 95% CI 0.38 
to 0.66). After excluding the breast cancer 
cases diagnosed at the first screening 
examination (i.e., the prevalent screening 
round), the rate of Stage II or higher breast 
cancer cases was 42% lower in screened 
women compared with the women 
diagnosed with breast cancer that had not 
been invited to screening (RR = 0.58, 95% CI 
0.45 to 0.74). Although the efficacy of 
mammography has been demonstrated, it 
does not achieve perfect sensitivity or 
specificity in women undergoing screening, 
and as such, the issue of adverse 
consequences for women who do and who 
do not have breast cancer has been a source 
of growing attention, and has become one of 
the core issues in recent debates about 
mammography. False negatives can be 
attributed to inherent technological 
limitations of mammography, quality 
assurance failures, and human error; false 
positives also can be attributed to these 
factors as well as to heightened medical-
legal concerns over the consequence of 
missed cancers. Further, in some instances, a 
patient’s desire for definitive findings in the 
presence of a low-suspicion lesion also 
contributes to false positives. The 
consequences of these errors include missed 
cancers, with potentially worse prognosis, 
as well as anxiety and harms associated with 
interventions for benign or nonobligate 
precursor lesions. There also is agreement 
that steps should be taken to reduce anxiety 
associated with screening73 and that there 
should be conscientious efforts applied 
toward informing women about the 
likelihood of both false-negative and false-
positive findings74. As use of 
mammography has increased, concerns 
have been raised about detection and 
overtreatment of DCIS75-77. Although the 
detection of DCIS is an inevitable 
consequence of mammographic screening, 
the concern that not all DCIS are progressive 
has to be weighed against the estimate that a 
substantial portion is progressive. Schwartz 
and colleagues have recommended that 
information provided to women undergoing 
mammography should include a discussion 
about detection of DCIS74.  
Diagnosis of invasive breast cancer in 
women aged 65 and older accounts for 
approximately 45 percent of all new breast 
cancer cases78 and diagnosis of breast cancer 
in women aged 65 and older accounts for 
about 45 percent of all breast cancer79. Breast 
cancer mortality increases with advancing 
age, ranging from 86 deaths per 100,000 
women aged 65 to 69 years to 200 deaths per 
100,000 women aged 85 years and older80. 
Although incidence and mortality rates are 
higher in older women, the question of 
screening in this population must be 
considered in the context of competing risks 
of death from co-morbid conditions, limited 
longevity, and a woman’s overall health 
status. Screening decisions in older women 
should be individualized by considering the 
potential benefits and risks of 
mammography in the context of current 
health status and estimated life 
expectancy80. If an individual has an 
estimated life expectancy of less than three 
to five years, severe functional limitations, 
and/or multiple or severe comorbidities 
likely to limit life expectancy, it may be 
appropriate to consider cessation of 
screening. Chronological age alone should 
not be the reason for the cessation of regular 
screening81- 86.  
 
Conclusion 
 
To conclude, during the last decade, breast 
cancer screening has gained wide acceptance 
by women and physicians, data supporting 
the efficacy of screening mammography 
have undergone intensive re-examination, 
and the benefits of regular mammography 
have been re-affirmed. At a time when the 
size of the population at risk for breast 
cancer is increasing every year, breast cancer
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 screening programs offer a significant 
reduction in the cancer-related mortality 
across the globe. This necessitates the 
establishment of a well-organized breast 
cancer screening system in the Kingdom of 
Saudi Arabia. Mammography is the key 
screening tool to detect and localize breast 
cancers. All recently introduced imaging 
gadgets are adjuncts to mammography. 
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